Logo

Illumina NextSeq 1000, P3 Reagent Kit for NextSeq 2000

Nov 12, 2020

Illumina's mid-throughput NextSeq 1000 sequencing system is now commercially available. The instrument offers 400 million reads per run and is more affordable than the NextSeq 2000. It has onboard informatics for rapid secondary analysis.

Illumina has also launched the P3 reagent kit for its NextSeq 2000 sequencing system. The high-output flow cell offers 1.1 billion reads per run, more than three times more than previously available on Illumina's mid-throughput systems. The kit will be available in four configurations: the 100-cycle kit delivers 110 Gb per run; the 200-cycle kit, 220 Gb; and the 300-cycle kit, 330 Gb. A 50-cycle kit is also available for infectious disease, small RNA, and spatial transcriptomics applications.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.